Lamyaa Gharawi

Lamyaa Gharawi

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2025 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
HAHussain Ali Almohammed
Hussain Ali Almohammed
HTHusna Irfan Thalib
Husna Irfan Thalib
KKKawthar Faisal Kushara
Kawthar Faisal Kushara
BSBushra Wadi Bin Saddiq
Bushra Wadi Bin Saddiq
BZBayan Mohammed Khair Al Zoabi
Bayan Mohammed Khair Al Zoabi
SAShaima Abuhulayqah
Shaima Abuhulayqah
Background: Vestibular migraine (VM) is a neurological disorder characterized by episodic vertigo in patients with migraine, contributing to substantial functional impairment. Although VM is relatively common, a consensus on effective prophylactic treatments is lacking. This systematic review aimed to evaluate the efficacy and safety of pharmacological and adjunct non‐pharmacological interventions for VM management. Methods: The systematic review was conducted following the PRISMA 2020 guidelines. PubMed, Web of Science, and Google Scholar were searched from inception to April 2025. Randomized controlled trials or cohort (retrospective and prospective) studies assessing prophylactic pharmacological or adjunct non‐pharmacological management in adults diagnosed with VM were included. The risk of bias was evaluated using the Cochrane RoB 2 and MINORS tools. Results: Nine studies (three RCTs, six cohort studies; total n = 687) met the inclusion criteria. Beta‐blockers, particularly propranolol, and antiepileptics, such as topiramate, consistently reduced VM symptoms, as measured using validated scales (Dizziness Handicap Inventory, Vertigo Symptom Scale, and Vestibular Activities of Daily Living). Anti‐CGRP monoclonal antibodies (erenumab and galcanezumab) showed favorable efficacy and tolerability. By contrast, calcium channel blockers and antidepressants yielded inconsistent outcomes. Vestibular rehabilitation, when used as an adjunct therapy, demonstrated functional benefits. Reported adverse effects were generally mild and treatment specific. Substantial heterogeneity in treatment protocols, outcome assessments, and follow‐up intervals precluded meta‐analysis; therefore, findings were synthesized qualitatively. Conclusion: Moderate‐quality evidence supports the use of propranolol and topiramate as first‐line prophylactic treatments for VM. Emerging data suggest that anti‐CGRP agents may be beneficial for refractory cases. Larger, rigorously designed trials are necessary to establish standardized and individualized treatment protocols.

17 September 2026 in NeuroSci
Verified
Journal Article
Open access
PDF file
AAAbdullah M Alkutbi
Abdullah M Alkutbi
HAHussain Ali Almohammed
Hussain Ali Almohammed
AMAhmed Salah Morad
Ahmed Salah Morad
BSBushra Wadi Bin Saddiq
Bushra Wadi Bin Saddiq
KKKawthar Faisal Kushara
Kawthar Faisal Kushara
LGLamyaa Gharawi
Lamyaa Gharawi
Background: Multiple trials have evaluated the benefits of endovascular thrombectomy (EVT) in patients with large-core ischemic stroke. This study aimed to determine the efficacy and safety of EVT compared with medical management (MM) alone in patients with large ischemic core infarcts. Methods: This study was registered in PROSPERO (CRD420261360129). A comprehensive search of PubMed, Web of Science, and the Cochrane Library was conducted to identify all relevant studies published up to April 2026. Effect sizes were calculated as risk ratios (RRs) using random-effects or fixed-effects models, as appropriate. Study quality was assessed using the Cochrane Risk of Bias tool and the Newcastle–Ottawa Scale. Subgroup and sensitivity analyses were performed to explore heterogeneity and evaluate outcomes across different patient populations. Outcomes assessed included excellent functional independence (mRS 0–2) and favorable functional outcome (mRS 0–3) at 3 months, mean mRS at 3 and 12 months, symptomatic intracranial hemorrhage, and all-cause mortality at 3 and 12 months. Results: Nine eligible studies (5 randomized controlled trials [RCTs] and 4 cohort studies; total sample size = 2252) were included to evaluate the comparative efficacy and safety of EVT versus MM alone in patients with acute ischemic stroke (AIS) secondary to large vessel occlusion. Our pooled analysis demonstrated a significantly higher rate of achieving a modified Rankin Scale (mRS) score of 0–2 in the EVT group compared with the MM group (RR = 2.64, 95% CI [1.79–3.90], p < 0.00001). Similarly, the likelihood of achieving an mRS score of 0–3 was significantly greater with EVT than with MM (RR = 1.78, 95% CI [1.40–2.26], p < 0.00001). The mean mRS score at 3 months was also significantly lower in the EVT group (MD = −0.58, 95% CI [−0.77 to −0.39], p < 0.00001). Safety outcomes were comparable between groups, with no significant differences in the rates of symptomatic intracranial hemorrhage (sICH) (RR = 1.36, 95% CI [0.88–2.11], p = 0.17) or mortality (RR = 0.96, 95% CI [0.65, 1.42], p = 0.84, I2 = 75%). Conclusions: Our findings suggest that EVT is associated with improved functional outcomes compared with MM alone, particularly in evidence derived from RCTs, while maintaining an acceptable safety profile. Further high-quality RCTs are warranted to strengthen the evidence base and validate these findings.